Posizolid

Posizolid
Clinical data
Other namesAZD2563
ATC code
  • none
Identifiers
IUPAC name
  • (5R)-3-[4-[1-[(2S)-2,3-Dihydroxypropanoyl]-3,6-dihydro-2H-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H21F2N3O7
Molar mass465.410 g·mol−1
3D model (JSmol)
SMILES
  • O=C1N(CC3=CC(F)=C(C4=CCN(C([C@@H](O)CO)=O)CC4)C(F)=C3)C[C@H](OC2=NOC=C2)O1
InChI
  • InChI=1S/C21H21F2N3O7/c22-15-7-13(26-9-14(33-21(26)30)11-31-18-3-6-32-24-18)8-16(23)19(15)12-1-4-25(5-2-12)20(29)17(28)10-27/h1,3,6-8,14,17,27-28H,2,4-5,9-11H2/t14-,17+/m1/s1 ☒N
  • Key:HBUJYEUPIIJJOS-PBHICJAKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Posizolid is an oxazolidinone antibiotic under investigation by AstraZeneca for the treatment of bacterial infections. At a concentration of 2 mg/L it inhibited 98% of all Gram-positive bacteria tested in vitro.[1]

Clinical trials

References

  1. ↑ Wookey A, Turner PJ, Greenhalgh JM, Eastwood M, Clarke J, Sefton C (March 2004). "AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro". Clinical Microbiology and Infection. 10 (3): 247–54. doi:10.1111/j.1198-743X.2004.00770.x. PMID 15008947.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.